We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Black Diamond Therapeutics Inc (BDTX) USD0.0001

Sell:$3.95 Buy:$3.97 Change: $0.03 (0.76%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Sell:$3.95
Buy:$3.97
Change: $0.03 (0.76%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Sell:$3.95
Buy:$3.97
Change: $0.03 (0.76%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. It also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).

Contact details

Address:
ONE MAIN STREET, 10TH FLOOR
CAMBRIDGE
02142
United States
Telephone:
+1 (617) 4175868
Website:
https://www.blackdiamondtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BDTX
ISIN:
US09203E1055
Market cap:
$143.83 million
Shares in issue:
36.23 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Epstein
    President, Chief Executive Officer, Director
  • Fang Ni
    Interim Chief Financial Officer
  • Brent Hatzis-Schoch
    Chief Operating Officer, General Counsel
  • Elizabeth Buck
    Executive Vice President - Discovery and Translational Sciences, Chief Scientific Officer
  • Karsten Witt
    Senior Vice President - Clinical Development, Interim Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.